Cytokinetics Inc CYTK:NASDAQ

Last Price$41.00NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22

Today's Change+1.71(4.35%)
Bid (Size)$40.92 (1)
Ask (Size)$42.90 (3)
Day Low / High$38.54 - 42.50
Volume7.4 M
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 07/01/2022

 

Cytokinetics Inc ( NASDAQ )

Price: $41.00
Change: +1.71 (4.35%)
Volume: 7.4 M
4:00PM ET 7/01/2022
 
 

Turning Point Therapeutics Inc ( NASDAQ )

Price: $75.11
Change: -0.14 (0.19%)
Volume: 2.2 M
4:00PM ET 7/01/2022
 
 

Karuna Therapeutics Inc ( NASDAQ )

Price: $126.10
Change: -0.41 (0.32%)
Volume: 353.0 K
4:00PM ET 7/01/2022
 
 

Mirati Therapeutics Inc ( NASDAQ )

Price: $71.18
Change: +4.05 (6.03%)
Volume: 849.4 K
4:00PM ET 7/01/2022
 
 

Amicus Therapeutics Inc ( NASDAQ )

Price: $10.80
Change: +0.06 (0.56%)
Volume: 3.8 M
4:00PM ET 7/01/2022
 

Read more news Recent News

Sector Update: Health Care Stocks Mixed Premarket Friday
9:14AM ET 7/01/2022 MT Newswires

Health care stocks were mixed premarket Friday. The Health Care SPDR (XLV) was 0.28% lower, and the iShares NASDAQ Biotechnology Index (IBB) was recently...

Cytokinetics Prices $450 Million Private Placement of Convertible Notes; Doubles Development Loan
4:00AM ET 7/01/2022 MT Newswires

Cytokinetics (CYTK) said Friday it has priced a private placement of $450 million principal amount of 3.5% convertible senior notes due 2027. Initial...

Sector Update: Health Care Stocks Swoon Late, Closing Lower
4:06PM ET 6/30/2022 MT Newswires

Health care stocks slipped fully below the surface this afternoon, with the NYSE Health Care Index falling 0.2% and the SPDR Health Care Select Sector ETF...

Sector Update: Health Care Stocks Little Changed on Thursday
1:59PM ET 6/30/2022 MT Newswires

Health care stocks were narrowly mixed this afternoon, with the NYSE Health Care Index sliding 0.1% while the SPDR Health Care Select Sector ETF (XLV) was...

Company Profile

Business DescriptionCytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA. View company web site for more details
Address350 Oyster Point Boulevard
South San Francisco, California 94080
Phone+1.650.624.3000
Number of Employees130
Recent SEC Filing06/24/20228-K
President, Chief Executive Officer & DirectorRobert I. Blum
Vice President-Development OperationsEric Terhaerdt
Chief Financial Officer & Senior Vice PresidentChing W. Jaw
Executive Vice President-Research & DevelopmentFady Ibraham Malik

Company Highlights

Price Open$42.50
Previous Close$39.29
52 Week Range$17.72 - 49.41
Market Capitalization$3.5 B
Shares Outstanding85.7 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.20
Beta vs. S&P 500N/A
Revenue$31.5 M
Net Profit Margin-396.22%
Return on Equity-164.73%

Analyst Ratings as of 01/31/2022

Buy
11
Overweight
2
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset